Encision Reports First Quarter Fiscal Year 2018 Results
BOULDER, Colo., July 27, 2017 /PRNewswire/ -- Encision Inc. (ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2018 first quarter that ended June 30, 2017.
The Company posted quarterly net revenue of $2.36 million for a quarterly net income of $181 thousand, or $0.02 per share. These results compare to net revenue of $2.28 million for a quarterly net loss of $99 thousand, or $(0.01) per share, in the year-ago quarter. Gross margin on net revenue was 57% in the fiscal 2018 first quarter and 52% in the fiscal 2017 first quarter. Net revenue for the current quarter included net revenue of $255 thousand from an order for non-AEM product. Gross margin on net revenue was higher in the current quarter as a result of product mix and lower costs in manufacturing operations.
Net cash of $108 thousand was generated by operations in the current quarter compared to net cash of $128 thousand used in operations in last year's quarter.
"We are pleased to have achieved profitability in the current quarter," said Greg Trudel, President and CEO. "We began selling our next-generation AEM® Burn Protection Cable and our next-generation durable monitors at the end of the quarter. Our next-generation durable monitor will make AEM® Safety adoption even more attractive for our customers and drive new levels of performance and growth. In our second quarter, we expect to complete the order for non-AEM product for additional net revenue of approximately $245 thousand. We expect that the second quarter will be profitable."
Encision Inc. designs and markets a portfolio of high performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures.
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2017 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.
CONTACT: Mala Ray, Encision Inc., 303-444-2600,
mray@encision.com
Encision Inc.
Unaudited Condensed Statements of Operations
(in thousands, except per share information)
Three Months Ended
------------------
June 30, 2017 June 30, 2016
------------- -------------
Net revenue $2,364 $2,277
Cost of revenue 1,020 1,087
Gross profit 1,344 1,190
----- -----
Operating expenses:
Sales and marketing 601 629
General and
administrative 324 344
Research and
development 221 302
--- ---
Total operating
expenses 1,146 1,275
----- -----
Operating income
(loss) 198 (85)
Interest and other
expense, net (17) (14)
--- ---
Income (loss) before
provision for income
taxes 181 (99)
Provision for income
taxes -- --
--- ---
Net income (loss) $181 $(99)
==== ====
Net income (loss) per
share-basic and
diluted $0.02 $(0.01)
Weighted average
number of shares-
basic 10,683 10,673
and diluted
Encision Inc.
Unaudited Condensed Balance Sheets
(in thousands)
June 30, 2017 March 31, 2017
------------- --------------
ASSETS
Cash and cash
equivalents $79 $45
Restricted cash 25 50
Accounts receivable,
net 984 1,042
Inventories, net 1,200 1,129
Prepaid expenses 122 62
--- ---
Total current assets 2,410 2,328
----- -----
Equipment, net 439 468
Patents, net 263 254
Other assets 17 17
--- ---
Total assets $3,129 $3,067
------ ------
LIABILITIES AND
SHAREHOLDERS'
EQUITY
Accounts payable $394 $403
Accrued compensation 212 268
Other accrued
liabilities 254 248
Line of credit 207 275
Deferred rent 30 30
Total current
liabilities 1,097 1,224
Deferred rent 33 41
Total liabilities 1,130 1,265
Common stock and
additional paid-in
capital 23,767 23,752
Accumulated (deficit) (21,768) (21,950)
------- -------
Total shareholders'
equity 1,999 1,802
----- -----
Total liabilities and
shareholders' equity $3,129 $3,067
------ ------
Encision Inc.
Unaudited Condensed Statements of Cash Flows
(in thousands)
Three Months
Ended
-------------
June 30, 2017 June 30, 2016
Operating
activities:
Net income (loss) $181 $(99)
Adjustments to
reconcile net
income (loss) to
cash
generated by (used
in) operating
activities:
Depreciation and
amortization 52 60
Share-based
compensation
expense 15 17
Recovery from
doubtful accounts,
net (15) (1)
Provision for
(recovery from)
inventory
obsolescence, net 10 (8)
Changes in
operating assets
and liabilities:
Accounts receivable 73 (105)
Inventories (82) 29
Prepaid expenses
and other assets (60) (77)
Accounts payable (9) 88
Accrued
compensation and
other accrued
liabilities (57) (32)
--- ---
Net cash generated
by (used in)
operating
activities 108 (128)
--- ----
Investing
activities:
Acquisition of
property and
equipment (16) (25)
Patent costs (15) (14)
--- ---
Net cash used in
investing
activities (31) (39)
--- ---
Financing
activities:
Paydown of credit
facility, net
change (68) (79)
Change in
restricted cash 25 --
--- ---
Net cash used in
financing
activities (43) (79)
--- ---
Increase (decrease)
in cash and cash
equivalents 34 (246)
Cash and cash
equivalents,
beginning of
period 45 293
--- ---
Cash and cash
equivalents, end
of period $79 $47
=== ===
View original content:http://www.prnewswire.com/news-releases/encision-reports-first-quarter-fiscal-year-2018-results-300494880.html
SOURCE Encision Inc.
